UK Dry Eye Treatment Market Overview

Dry Eye Syndrome Treatment Market size was valued at USD 5.48 Bn in 2023, registering a CAGR of 7.03 % during the forecast period (2024-2032), and the market is projected to be worth USD 10.1 Bn by 2032

Dry eye, medically known as keratoconjunctivitis sicca, is an ocular disorder caused by the lack of tear fluid to lubricate the eyes. This can be an indicator of either low production of tears or rapid evaporation of the film of tears on the surface of the eyes, which can be brought about by several conditions.

• The market for treating dry eye targets a common issue caused by either insufficient tear production or rapid tear evaporation, resulting in discomfort and possible vision problems. This market includes a range of products and treatments designed to reduce symptoms and enhance tear production and retention.
• Important treatment options consist of OTC lubricating eye drops called artificial tears, as well as prescribed medications such as cyclosporine and lifitegrast to lower inflammation and enhance tear formation. Punctal plugs, used to block tear drainage in tear ducts, along with lifestyle changes like raising humidity levels at home and wearing protective eyewear, are frequently utilized treatments.
• Factors driving the market include the rising occurrence of dry eye syndrome in the elderly demographic and the increased usage of digital devices that may lead to eye strain. Furthermore, factors in the environment such as pollution and extended periods of air conditioning use also play a role in the increasing prevalence of the condition.

Market Dynamics And Factors For UK Dry Eye Treatment Market

Drivers:

Rising Prevalence of Dry Eye Disease

• According to a published article in PubMed in 2018, epidemiological studies from the Women’s Health Study and Physician’s Health observed that dry eye prevalence increases in women and men every five years after 50, with greater prevalence in women, compared to men. Tear dysfunction has a reported prevalence ranging from 2% to 14.2%. Older adults are particularly susceptible to inadequate tear production because of lacrimal gland dysfunction, altered reflex secretion, diminished corneal sensation, or inflammatory destruction of lacrimal glands. The aging population is more prone to various eye disorders, which is expected to propel the market growth of the UK dry eye market. Moreover, as per a study conducted by researchers in the UK in May 2020, young adults showed relatively high rates of dry eye symptoms. This factor is projected to propel market growth in the near future.

Restraints:

Limited Awareness Related To Dry Eye Disease

• The awareness related to eye health is found low among the UK population, which is acting as restraining the market growth. Also, there is a lack of attention given to this disease. People often visit ophthalmologists until there are some major symptomatic conditions. A survey conducted in the UK observed that one in four adults is not found to conduct an eye test every two years as recommended by NHS. There is a high level of ignorance among the population, especially among the youngsters. This factor is limiting the growth of the UK dry eye disease market.

Opportunity:

Collaboration of Market Players

• Emerging markets are anticipated to offer potential growth opportunities for the market players in the UK during the forecast period due to the rising prevalence of dry eye disease and the rising number of pipeline drugs for DED. Players in the UK dry eye market are competing to provide better patient care. Furthermore, many emerging players in the market are adopting strategies, such as acquisitions and mergers, to increase their product portfolio by launching new products and collaborations of major players with organizations. For instance, in February 2016, in Europe, Essilor International strengthened its online optical products retailing business with the acquisition of Vision Direct Group Ltd, based in the UK. Vision Direct does a majority of its business in the UK and Ireland but is also active in several other European countries. This move further strengthens Essilor International’s position in online optical retail in Europe.

Segmentation Analysis of UK Dry Eye Treatment Market

• By Product, The liquid drops segment held the largest share for UK Dry Eye Treatment Market. Liquid drops are saline-containing drops for ocular route of administration. The liquid drop contains steroids, antihistamines, sympathomimetics, beta receptor blockers, parasympathomimetics, parasympatholytics, prostaglandins, nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, antifungals, or topical anesthetics. Liquid drops are generally safe for patients to use. A Gel segment is a semi-solid medication that can have properties ranging from soft and weak to hard and tough. Gels are light with a silky texture containing medical content, which reduces the puffiness of the eyes. This gel provides long-lasting lubrication to the eyes and provides relief in dry eye conditions. Liquid wipes segment is another commonly used product for dry eye condition. It is known as liquid towel or disinfecting wipes, which are small, pre-moistened pieces of paper or fabric. They are used for reducing dry eyes and maintain moisture in the eye. Eye ointment segment is a drug in semi-solid and greasy form. Once the eye ointment is applied to the patient eye, it breaks into small drops. Eye ointment mainly consists of various preservatives and medicines such as Chlorbutol, benzalkonium chloride, thiomersal, and organomercuric compounds.
• By Distribution Channel, A retail pharmacy segment held the largest share for UK Dry Eye Treatment Market. Retail Pharmacy is a store where the general public can get their prescriptions filled. Retail pharmacies provide dry eye drugs, drops, and ointment to patients. E-commerce segment is projected to witness highest growth during the forecast period. E-commerce pharmacy is type of distribution channel in which dry eye-related products are suppled over the internet and sent to customers by the shipping companies, mail or online web portal. Others include wholesalers, stockists, third-party suppliers who distribute medical-related products to customers.

Top Key Players Covered In UK Dry Eye Treatment Market

• Allergan plc
• Bausch and Lomb Pvt Ltd
• Santen Pharmaceutical Co., Ltd
• Otsuka pharmaceutical Co Ltd
• Teva Pharmaceutical Industries Ltd
• Johnson & Johnson Services Inc
• Novartis AG
• I-MED Pharma
• Lenstore
• Vision Direct
• Carl Zeiss AG
• Alcon Inc.
• Regeneron Pharmaceuticals
• Hoya Corporation
• Aerie Pharmaceuticals, Inc.
• CooperVision
• Mediwound Ltd.
• EyePoint Pharmaceuticals, Inc.
• Glaukos Corporation
• Shire plc

Key Industry Developments In The UK Dry Eye Treatment Market

• In July 2024, Alcon announced the completion of its acquisition of Belkin Vision, the developer of the Belkin Vision Eagle direct selective laser trabeculoplasty (DSLT) for treating glaucoma. The agreement included a total upfront consideration of $81 million, comprising an approximate cash payment of $65 million. Additionally, the deal featured the potential for up to $385 million in payments contingent on achieving sales-based milestones. This acquisition aimed to enhance Alcon’s portfolio in the glaucoma treatment market, reflecting the company’s commitment to advancing innovative eye care solutions.
• In September 2023, Bausch + Lomb Corporation (NYSE/TSX: BLCO), a prominent global eye health company committed to enhancing vision and overall well-being, announced the completion of its acquisition of XIIDRA (lifitegrast ophthalmic solution) 5%. This non-steroidal eye drop was specifically approved for treating the signs and symptoms of dry eye disease (DED), particularly focusing on inflammation associated with the condition, along with certain other ophthalmology assets.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Product
 3.2 By Drugs
 3.3 By End User

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: UK Dry Eye Treatment Market by Product
 5.1 UK Dry Eye Treatment Market Overview Snapshot and Growth Engine
 5.2 UK Dry Eye Treatment Market Overview
 5.3 Liquid Drops
  5.3.1 Introduction and Market Overview
  5.3.2 Key Market Trends, Growth Factors and Opportunities
  5.3.3 Impact of Covid-19
  5.3.4 Historic and Forecasted Market Size (2017-2032F)
  5.3.5 Key Market Trends, Growth Factors and Opportunities
  5.3.6 Liquid Drops: Geographic Segmentation
 5.4 Gel
  5.4.1 Introduction and Market Overview
  5.4.2 Key Market Trends, Growth Factors and Opportunities
  5.4.3 Impact of Covid-19
  5.4.4 Historic and Forecasted Market Size (2017-2032F)
  5.4.5 Key Market Trends, Growth Factors and Opportunities
  5.4.6 Gel: Geographic Segmentation
 5.5 Liquid Wipes
  5.5.1 Introduction and Market Overview
  5.5.2 Key Market Trends, Growth Factors and Opportunities
  5.5.3 Impact of Covid-19
  5.5.4 Historic and Forecasted Market Size (2017-2032F)
  5.5.5 Key Market Trends, Growth Factors and Opportunities
  5.5.6 Liquid Wipes: Geographic Segmentation
 5.6 Eye Ointment
  5.6.1 Introduction and Market Overview
  5.6.2 Key Market Trends, Growth Factors and Opportunities
  5.6.3 Impact of Covid-19
  5.6.4 Historic and Forecasted Market Size (2017-2032F)
  5.6.5 Key Market Trends, Growth Factors and Opportunities
  5.6.6 Eye Ointment: Geographic Segmentation

Chapter 6: UK Dry Eye Treatment Market by Drugs
 6.1 UK Dry Eye Treatment Market Overview Snapshot and Growth Engine
 6.2 UK Dry Eye Treatment Market Overview
 6.3 Artificial Lubricant Eye Drops
  6.3.1 Introduction and Market Overview
  6.3.2 Key Market Trends, Growth Factors and Opportunities
  6.3.3 Impact of Covid-19
  6.3.4 Historic and Forecasted Market Size (2017-2032F)
  6.3.5 Key Market Trends, Growth Factors and Opportunities
  6.3.6 Artificial Lubricant Eye Drops: Geographic Segmentation
 6.4 Anti-Inflammatory Drugs
  6.4.1 Introduction and Market Overview
  6.4.2 Key Market Trends, Growth Factors and Opportunities
  6.4.3 Impact of Covid-19
  6.4.4 Historic and Forecasted Market Size (2017-2032F)
  6.4.5 Key Market Trends, Growth Factors and Opportunities
  6.4.6 Anti-Inflammatory Drugs: Geographic Segmentation
 6.5 Autologous Serum Eye Drops
  6.5.1 Introduction and Market Overview
  6.5.2 Key Market Trends, Growth Factors and Opportunities
  6.5.3 Impact of Covid-19
  6.5.4 Historic and Forecasted Market Size (2017-2032F)
  6.5.5 Key Market Trends, Growth Factors and Opportunities
  6.5.6 Autologous Serum Eye Drops: Geographic Segmentation

Chapter 7: UK Dry Eye Treatment Market by End User
 7.1 UK Dry Eye Treatment Market Overview Snapshot and Growth Engine
 7.2 UK Dry Eye Treatment Market Overview
 7.3 Hospital Pharmacies
  7.3.1 Introduction and Market Overview
  7.3.2 Key Market Trends, Growth Factors and Opportunities
  7.3.3 Impact of Covid-19
  7.3.4 Historic and Forecasted Market Size (2017-2032F)
  7.3.5 Key Market Trends, Growth Factors and Opportunities
  7.3.6 Hospital Pharmacies: Geographic Segmentation
 7.4 Retail Pharmacies
  7.4.1 Introduction and Market Overview
  7.4.2 Key Market Trends, Growth Factors and Opportunities
  7.4.3 Impact of Covid-19
  7.4.4 Historic and Forecasted Market Size (2017-2032F)
  7.4.5 Key Market Trends, Growth Factors and Opportunities
  7.4.6 Retail Pharmacies: Geographic Segmentation
 7.5 E-Commerce
  7.5.1 Introduction and Market Overview
  7.5.2 Key Market Trends, Growth Factors and Opportunities
  7.5.3 Impact of Covid-19
  7.5.4 Historic and Forecasted Market Size (2017-2032F)
  7.5.5 Key Market Trends, Growth Factors and Opportunities
  7.5.6 E-Commerce: Geographic Segmentation
 7.6 Others
  7.6.1 Introduction and Market Overview
  7.6.2 Key Market Trends, Growth Factors and Opportunities
  7.6.3 Impact of Covid-19
  7.6.4 Historic and Forecasted Market Size (2017-2032F)
  7.6.5 Key Market Trends, Growth Factors and Opportunities
  7.6.6 Others: Geographic Segmentation

Chapter 8: Company Profiles and Competitive Analysis
 8.1 Competitive Landscape
  8.1.1 Competitive Positioning
  8.1.2 UK Dry Eye Treatment Sales and Market Share By Players
  8.1.3 Industry BCG Matrix
  8.1.4 Ansoff Matrix
  8.1.5 UK Dry Eye Treatment Industry Concentration Ratio (CR5 and HHI)
  8.1.6 Top 5 UK Dry Eye Treatment Players Market Share
  8.1.7 Mergers and Acquisitions
  8.1.8 Business Strategies By Top Players
 8.2 ALLERGAN PLC
  8.2.1 Company Overview
  8.2.2 Key Executives
  8.2.3 Company Snapshot
  8.2.4 Operating Business Segments
  8.2.5 Product Portfolio
  8.2.6 Business Performance
  8.2.7 Key Strategic Moves and Recent Developments
  8.2.8 SWOT Analysis
 8.3 BAUSCH AND LOMB PVT LTD
 8.4 SANTEN PHARMACEUTICAL CO.
 8.5 LTD
 8.6 OTSUKA PHARMACEUTICAL CO LTD
 8.7 TEVA PHARMACEUTICAL INDUSTRIES LTD
 8.8 JOHNSON & JOHNSON SERVICES INC
 8.9 NOVARTIS AG
 8.10 I-MED PHARMA
 8.11 LENSTORE
 8.12 VISION DIRECT
 8.13 OTHER MAJOR PLAYERS

Chapter 9 Investment Analysis

Chapter 10 Analyst Viewpoint and Conclusion

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. UK DRY EYE TREATMENT MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. UK DRY EYE TREATMENT MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. UK DRY EYE TREATMENT MARKET COMPETITIVE RIVALRY
TABLE 005. UK DRY EYE TREATMENT MARKET THREAT OF NEW ENTRANTS
TABLE 006. UK DRY EYE TREATMENT MARKET THREAT OF SUBSTITUTES
TABLE 007. UK DRY EYE TREATMENT MARKET BY PRODUCT
TABLE 008. LIQUID DROPS MARKET OVERVIEW (2016-2028)
TABLE 009. GEL MARKET OVERVIEW (2016-2028)
TABLE 010. LIQUID WIPES MARKET OVERVIEW (2016-2028)
TABLE 011. EYE OINTMENT MARKET OVERVIEW (2016-2028)
TABLE 012. UK DRY EYE TREATMENT MARKET BY DRUGS
TABLE 013. ARTIFICIAL LUBRICANT EYE DROPS MARKET OVERVIEW (2016-2028)
TABLE 014. ANTI-INFLAMMATORY DRUGS MARKET OVERVIEW (2016-2028)
TABLE 015. AUTOLOGOUS SERUM EYE DROPS MARKET OVERVIEW (2016-2028)
TABLE 016. UK DRY EYE TREATMENT MARKET BY END USER
TABLE 017. HOSPITAL PHARMACIES MARKET OVERVIEW (2016-2028)
TABLE 018. RETAIL PHARMACIES MARKET OVERVIEW (2016-2028)
TABLE 019. E-COMMERCE MARKET OVERVIEW (2016-2028)
TABLE 020. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 021. UK DRY EYE TREATMENT MARKET, BY PRODUCT (2016-2028)
TABLE 022. UK DRY EYE TREATMENT MARKET, BY DRUGS (2016-2028)
TABLE 023. UK DRY EYE TREATMENT MARKET, BY END USER (2016-2028)
TABLE 024. UK DRY EYE TREATMENT MARKET, BY COUNTRY (2016-2028)
TABLE 025. ALLERGAN PLC: SNAPSHOT
TABLE 026. ALLERGAN PLC: BUSINESS PERFORMANCE
TABLE 027. ALLERGAN PLC: PRODUCT PORTFOLIO
TABLE 028. ALLERGAN PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 028. BAUSCH AND LOMB PVT LTD: SNAPSHOT
TABLE 029. BAUSCH AND LOMB PVT LTD: BUSINESS PERFORMANCE
TABLE 030. BAUSCH AND LOMB PVT LTD: PRODUCT PORTFOLIO
TABLE 031. BAUSCH AND LOMB PVT LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 031. SANTEN PHARMACEUTICAL CO.: SNAPSHOT
TABLE 032. SANTEN PHARMACEUTICAL CO.: BUSINESS PERFORMANCE
TABLE 033. SANTEN PHARMACEUTICAL CO.: PRODUCT PORTFOLIO
TABLE 034. SANTEN PHARMACEUTICAL CO.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 034. LTD: SNAPSHOT
TABLE 035. LTD: BUSINESS PERFORMANCE
TABLE 036. LTD: PRODUCT PORTFOLIO
TABLE 037. LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 037. OTSUKA PHARMACEUTICAL CO LTD: SNAPSHOT
TABLE 038. OTSUKA PHARMACEUTICAL CO LTD: BUSINESS PERFORMANCE
TABLE 039. OTSUKA PHARMACEUTICAL CO LTD: PRODUCT PORTFOLIO
TABLE 040. OTSUKA PHARMACEUTICAL CO LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 040. TEVA PHARMACEUTICAL INDUSTRIES LTD: SNAPSHOT
TABLE 041. TEVA PHARMACEUTICAL INDUSTRIES LTD: BUSINESS PERFORMANCE
TABLE 042. TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
TABLE 043. TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 043. JOHNSON & JOHNSON SERVICES INC: SNAPSHOT
TABLE 044. JOHNSON & JOHNSON SERVICES INC: BUSINESS PERFORMANCE
TABLE 045. JOHNSON & JOHNSON SERVICES INC: PRODUCT PORTFOLIO
TABLE 046. JOHNSON & JOHNSON SERVICES INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 046. NOVARTIS AG: SNAPSHOT
TABLE 047. NOVARTIS AG: BUSINESS PERFORMANCE
TABLE 048. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 049. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 049. I-MED PHARMA: SNAPSHOT
TABLE 050. I-MED PHARMA: BUSINESS PERFORMANCE
TABLE 051. I-MED PHARMA: PRODUCT PORTFOLIO
TABLE 052. I-MED PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 052. LENSTORE: SNAPSHOT
TABLE 053. LENSTORE: BUSINESS PERFORMANCE
TABLE 054. LENSTORE: PRODUCT PORTFOLIO
TABLE 055. LENSTORE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 055. VISION DIRECT: SNAPSHOT
TABLE 056. VISION DIRECT: BUSINESS PERFORMANCE
TABLE 057. VISION DIRECT: PRODUCT PORTFOLIO
TABLE 058. VISION DIRECT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 058. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 059. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 060. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 061. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. UK DRY EYE TREATMENT MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. UK DRY EYE TREATMENT MARKET OVERVIEW BY PRODUCT
FIGURE 012. LIQUID DROPS MARKET OVERVIEW (2016-2028)
FIGURE 013. GEL MARKET OVERVIEW (2016-2028)
FIGURE 014. LIQUID WIPES MARKET OVERVIEW (2016-2028)
FIGURE 015. EYE OINTMENT MARKET OVERVIEW (2016-2028)
FIGURE 016. UK DRY EYE TREATMENT MARKET OVERVIEW BY DRUGS
FIGURE 017. ARTIFICIAL LUBRICANT EYE DROPS MARKET OVERVIEW (2016-2028)
FIGURE 018. ANTI-INFLAMMATORY DRUGS MARKET OVERVIEW (2016-2028)
FIGURE 019. AUTOLOGOUS SERUM EYE DROPS MARKET OVERVIEW (2016-2028)
FIGURE 020. UK DRY EYE TREATMENT MARKET OVERVIEW BY END USER
FIGURE 021. HOSPITAL PHARMACIES MARKET OVERVIEW (2016-2028)
FIGURE 022. RETAIL PHARMACIES MARKET OVERVIEW (2016-2028)
FIGURE 023. E-COMMERCE MARKET OVERVIEW (2016-2028)
FIGURE 024. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 025. UK DRY EYE TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)